Anna Donald on

2007-09-12T00:00:00

The summer witnessed another episode in the ongoing ‘rationing’ saga about NHS provision of the Alzheimer drugs rivastigmine, donepezil, and galantamine. The High Court upheld the substance of NICE’s guidance, which means that these drugs continue to be recommended only for people with ‘moderate’ Alzheimer’s.

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant
  • 10 expert briefings every fortnight (Premium only)

Subscribe

to HSJ

Already a subscriber? Sign into your account here